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Edited by Horst FeldmannAbstract Caveolin-3 (Cav-3) is the main scaﬀolding protein
present in myoﬁber caveolae. We transfected C2C12 myoblasts
with dominant negative forms of Cav-3, P104L or DTFT respec-
tively, which cause the limb-girdle muscular dystrophy 1-C. Both
these forms triggered Cav-3 loss during C2C12 cell diﬀerentia-
tion. The P104L mutation reduced myoﬁber formation by im-
paired AKT signalling, accompanied by dramatic expression of
the E3 ubiquitin ligase Atrogin. On the other hand, the DTFT
mutation triggered hypertrophic myotubes sustained by pro-
longed AKT activation, but independent of increased levels of
follistatin and interleukin-4 expression. These data suggest that
separated mutations within the same dystrophy-related gene may
cause muscle degeneration through diﬀerent mechanisms.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Caveolin 3 (Cav-3) is a muscle-speciﬁc scaﬀolding protein
which recruits lipids and several signalling and structural pro-
teins in caveolae [1–3]. Cav-3 expression occurs normally dur-
ing myoﬁber diﬀerentiation and hypertrophy through
activation of both p38 and PI3-kinase/AKT pathways [4,5],
whereas its expression results down-regulated during atrophy,
suggesting its role causally linked to myoﬁber maturation [5].
Diﬀerent human Cav-3 mutations have been characterized
to cause four muscle disease phenotypes, including limb-girdle
muscular dystrophy, rippling muscle disease, distal myopathy
and hyperCKemia [3]: most of these mutations give rise to
dominant negative forms which oligomerize with the wild type
Cav-3, leading to protein loss. In particular, two heterozygous
mutations were ﬁrst identiﬁed within the Cav-3 gene as respon-
sible of the autosomal dominant limb-girdle muscular dystro-Abbreviations: DMEM, Dulbecco’s modiﬁed Eagle’s medium; FBS,
fetal bovine serum; HS, horse serum; MHC, myosin heavy chain;
NFATC, nuclear factor of activated T-cells; IL-4, Interleukin 4
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doi:10.1016/j.febslet.2007.09.055phy 1-C (LGMD-1C) [6], consisting of a 9-bp microdeletion
(DTFT) in the caveolin-scaﬀolding domain and a missense
mutation (P104L) in the transmembrane domain. These mu-
tated proteins are not properly targeted to plasma membrane,
being retained in the Golgi and endoplasmic reticulum com-
partments, where they form unstable aggregates with wild type
Cav-3 undergoing proteosomal degradation [7].
In the last years, many aspects emerged from the character-
ization of LGMD-1C mutants, underlying that diﬀerent mech-
anisms occur during myoﬁber degeneration induced by loss of
Cav-3. In particular, transgenic mice harboring the Cav-3
P104L mutation were characterized by a severe myopathy
accompanied by increase of nitric oxide synthase activity and
myostatin type I receptor activation [8,9], whereas the expres-
sion of P104L caused in zebraﬁsh severe disruption of muscle
diﬀerentiation [10]. On the other side, myoblasts expressing
DTFT mutation underwent apoptosis by altered Src localiza-
tion [11] and resulted more susceptible to oxidative stress by
alteration of PI3-kinase signalling [12].
Here we generated C2C12 myoblasts stably transfected with
the vectors harboring either the P104L or DTFT Cav-3 muta-
tions, demonstrating that these forms diﬀerentially aﬀect myo-
blast diﬀerentiation leading to distinct cell behaviors.2. Materials and methods
2.1. Materials
All the reagents are from Sigma–Aldrich, if not otherwise indicated.
2.2. Cell culture
The mouse C2C12 myoblasts were maintained at subconﬂuent den-
sity at 37C in 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) high glucose supplemented with 10% fetal bovine serum
(FBS) and 100 lg/ml penicillin–streptomycin. To induce diﬀerentia-
tion, conﬂuent cells were shifted to a medium containing DMEM sup-
plemented with 2% horse serum (HS). To quantify the myotube
number and diameter, 10 ﬁelds were chosen randomly and 10 myotu-
bes were measured per ﬁeld. The number and the average diameter
taken along the length of the myotube were the mean of 10
measurements.2.3. Stable transfections
C2C12 myoblasts were cotransfected by Lipofectamine 2000 reagent
(Invitrogen) with the vector harboring the Cav-3 mutation (pCAGGS-
P104L or DTFT) in presence of a pcDNA vector conferring the genet-
icin resistance (0.5 mg/ml).blished by Elsevier B.V. All rights reserved.
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Cav-3 was detected with a mouse monoclonal antibody (clone 26,
BD Transduction Laboratories) in the insoluble membranous fraction
obtained upon centrifugation (12000 · g for 15 min at 4 C) of the cells
harvested in a Triton buﬀer composed by 10 mM Tris pH 8.0, 0.15 M
NaCl, 5 mM EDTA, 1% Triton X-100, protease inhibitors (Roche
Molecular Biochemicals). Antibodies for the phosphorylated Ser473
of AKT (Cell Signalling), myogenin (Santa Cruz Biotechnology, clone
F5D), the phosphorylated form of P70S6K (Cell Signalling) and myo-
sin heavy chain (MHC) (Hybridoma Bank, University of Iowa) were
used on cleared extracts from cells harvested in RIPA lysis buﬀer
(20 mM Tris–HCl pH 7.6, 50 mM NaCl, 1% Nonidet P40, 0.5% so-
dium deoxycholate, 0.1% SDS, protease inhibitors). An antibody
against alpha tubulin was used to normalize the loading.
2.5. Semiquantitative RT-PCR analysis
Total RNA was obtained by Tri-reagent extraction, digested with 1
unit of DNAase (DNA-free, Ambion), and retrotranscribed (2 lg) with
400 UofMMLV-RT (Promega). The primers (250 nM)were as follows:
follistatin forward primer: 5 0-CTCTTCAAGTGGATGATTTTC; re-
verse: 5 0-ACAGTAGGCATTATTGGTCTG; NFATC2 forward
primer: 5 0-CTTCAGATCTTCATTGGGACAGCA; reverse: 5 0-GC-
AGCTGTCCATGTCTTGTCTCTC; Interleukin 4 (IL-4) forward pri-
mer: 5 0-TTTCTCGAATGTACCAGGAGCCATA; reverse: 5 0-GG-
ACTCATTCATGGTGCAGCTTATC.
2.6. Real-time PCR analysis
Quantitative PCR was performed with a Biorad iCycler iQ Real-
time PCR Detection System using a iQ SYBR Green Supermix (Bio-
rad) according to the manufacturer’s instructions. The primers
(250 nM) were as follows: Murf-1 forward primer: 5 0-GGTGCCT-
ACTTGCTCCTTGT; reverse: 5 0-CTGGTGGCTATTCTCCTTGG;
Atrogin forward primer: 5 0-CGACCTGCCTGTGTGCTTAC; re-
verse: 5 0-CTTGCGAATCTGCCTCTCTG. All PCR reactions were
performed in 96-well optical plates (Biorad) containing primers, 8 ng
of cDNA, and 10 ll of reaction mix in a total volume of 20 ll. Gene
expression levels were normalized to gapdh mRNA expression.2.7. Statistics
All of the data are expressed as means ± S.E. Statistical signiﬁcance
was determined using t-student analysis. A P value of <0.05 was con-
sidered signiﬁcant.3. Results and discussion
3.1. Expression of Cav-3 mutants diﬀerentially aﬀects C2C12
cell diﬀerentiation
Among the several mutations occurring within Cav-3 gene,
the missense mutation P104L and the tripeptide deletion
DTFT cause the autosomal dominant form of limb-girdle mus-
cular dystrophy 1-c (LGMD-1C) [6,7].
We generated C2C12 myoblasts stably transfected with
either the dominant negative P104L or DTFT mutants
(LGMD-1C myoblasts), which were tested for transgene
expression in proliferating myoblasts (Fig. 1A), whereas
endogenous Cav-3 was absent in parental C2C12 cells. As
shown in Fig. 1B, as parental C2C12 cells exhibited the normal
formation of multinucleated myotubes over a time-course dif-
ferentiation, both LGMD-1C myoblasts displayed an evident
opposite phenotypic behavior: P104L cells showed a severe
undiﬀerentiated phenotype, whereas DTFT cells formed multi-
giant myotubes. Western blot analysis (Fig. 1C) showed the
gradual increase of Cav-3 expression in diﬀerentiating parental
cells, whereas protein loss was observed in both LGMD-1C
myoblasts, as conﬁrmed by the relative band quantiﬁcations.
As shown in Fig. 1D (left panel), the myotube number in
P104L myoblasts was severely reduced, as very few thinmyoﬁbers were observed, while DTFT cells maintained the
ability to form myotubes, although with a signiﬁcantly reduced
fashion compared to parental cells. Remarkably, the average
size of DTFT myotubes was increased of about twofold com-
pared to control myoﬁbers (Fig. 1D, right panel). We therefore
investigated the molecular mechanisms underlying the pheno-
type of LGMD-1C myoblasts, ﬁrst analysing by Immunoblot
the time-course expression of both phosphorylated AKT form
and myogenin (Fig. 2A), two key markers of myoblast diﬀer-
entiation. As parental cells showed a transient AKT activation,
reaching a peak at day 3 paralleled by increased myogenin
expression, P104L cells displayed impaired AKT activation
accompanied by almost undetectable myogenin expression.
On the other side, the behavior of DTFT cells was character-
ized by a long lasting increase of AKT phosphorylation paral-
leled by increase of myogenin; accordingly, the
phosphorylation of the downstream AKT target P70S6K
(Fig. 2B) was more sustained in DTFT myotubes due to
AKT overactivation, while a low signal was present in P104
myoblasts. The expression of MHC (Fig. 2C), a marker of ter-
minal diﬀerentiation, was even observed in DTFT myotubes to
precede that in parental myotubes, while it was undetectable in
P104L myoblasts. Altogether these results suggest that while
P104L mutation seems to interfere with the formation of myo-
tubes by important attenuation of AKT pathway, as com-
monly characterized for both reduced diﬀerentiation and
myoﬁber atrophy [13,14], the DTFT mutation confers to
C2C12 myotubes an hypertrophic-like phenotype by sustained
activation of AKT, a key step for developing muscle hypertro-
phy [15].
To next evaluate whether the increased size of DTFT myotu-
bes was due to augmented myoblast recruitment, we investi-
gated by RT-PCR analysis the expression of some speciﬁc
markers such as follistatin [16], NFATC2 and IL-4 [17]
(Fig. 2D), which promote myoﬁber growth by diﬀerent mech-
anisms. As a long lasting increase of follistatin transcript was
evident during diﬀerentiation of parental cells, both the
LGMD-1C mutants exhibited signiﬁcant down-regulation of
follistatin expression. In addition, NFATC2 expression re-
sulted down-regulated in P104L cells, while it appeared only
slightly decreased in DTFT myotubes. Finally, we did not de-
tect the expression of IL-4 nor in parental neither in LGMD-
1C myoblasts at diﬀerent stages of myotube formation. There-
fore, the phenotypic behavior of DTFT cells seems to be likely
due to increased AKT activation, rather than related to in-
creased follistatin or NFATC2/IL-4 expression. Although the
behavior of DTFT cells results elusive, it has been demon-
strated that Duchenne and limb-girdle muscular dystrophies
are characterized by repeated cycles of myoblast degenera-
tion/regeneration, accompanied by hypertrophic ﬁbers with
elevated AKT signalling [18], in part conﬁrming the main clin-
ical features of the patients with Cav-3 deﬁciency, which
showed mild-to-moderate proximal muscle weakness accom-
panied by calf hypertrophy [6]. However, it remains to estab-
lish how diﬀerent mutations within Cav-3 gene have such
diﬀerent consequences on AKT activation.
3.2. The expression of Atrogin and Murf-1 is dysregulated in
LGMD-1C myoblasts
We next focused on the expression of two muscle-speciﬁc
ubiquitin ligases (E3 proteins), Atrogin/MAFbx and Murf-1
[19], whose expression is dramatically increased during cata-
Fig. 1. Expression of P104L and DTFT Cav-3 related mutations aﬀects myoblast diﬀerentiation. (A) P104L and DTFT transgene expression was
evaluated in transfected myoblasts by Immunoblot analysis of Cav-3 expression. (B) C2C12, P104L and DTFT cell morphology was visualized after
72 h of diﬀerentiation. Scale bars indicate the same magniﬁcation. (C) Western blot analysis of Cav-3 expression in parental and LGMD-1C
myoblasts over a time-course diﬀerentiation. The relative quantiﬁcations in the graphs were expressed as ratio between Cav-3 and tubulin expression.
(D) Mean myotube number (left panel) and mean myotube size (right panel) are expressed in arbitrary units (n = 10, *P < 0.05).
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tion via the ubiquitin-proteasome pathway [20–22]. In particu-lar, it has been shown that P104L mutant transgenic mice
display skeletal muscle atrophy due to overactivation of the
Fig. 2. Western blot analysis was performed over a 4 days time-course diﬀerentiation on C2C12 and LGMD-1C myoblasts to detect the
phosphorylated AKT form and myogenin (A), the phosphorylated P70S6K form (B), and MHC (C). The data were normalized using tubulin as
control. (D) RT-PCR analysis was performed over a time-course diﬀerentiation of parental and LGMD-1C myoblasts to detect the transcript proﬁle
of follistatin, NFATC2 and IL-4. Activated T lymphocytes stimulated with concanavalin A were used as positive control for 40 cycles of IL-4
ampliﬁcation.
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atively regulate the skeletal muscle size [23]. Since myostatin
signalling appears to antagonize the canonical hypertrophic
PI3-kinase/AKT pathway, leading to activation of the ubiqui-
tin proteolytic system [24], we performed quantitative RT-PCR analysis to detect whether the expression of Murf-1 and
Atrogin would change during the defective diﬀerentiation of
LGMD-1C cells (Fig. 3). While the expression of Murf-1 re-
sulted signiﬁcantly down-regulated in both LGMD-1C cells
(Fig. 3A), with a more severe eﬀect on P104L cells compared
Fig. 3. Quantitative real-time PCR analysis of Murf-1 and Atrogin expression in C2C12 and LGMD-1C myoblasts. The amount of Murf-1 (A) and
Atrogin (B) mRNA was analyzed by quantitative RT-PCR over a four days time-course diﬀerentiation and normalized to gapdh mRNA content
(n = 2, *P < 0.05). Representative semiquantitative RT-PCR are shown on the right of each graph.
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ically up-regulated only in P104L myoblasts over the full-time
course diﬀerentiation (Fig. 3B). The speciﬁc ability of P104L
mutation to trigger Atrogin increase suggests that a sustained
protein turn-over might impair the myoﬁber formation in these
myoblasts, whose behavior in part reﬂects the phenotype of
P104L mice, where enhanced myostatin signalling causes myo-
ﬁber atrophy [9]. On the contrary, the ability of DTFT muta-
tion to sustain the AKT signalling might preserve the cells
from atrophy, leading to formation of abnormal hypertrophic
myoﬁbers. Finally, the down-regulation of Murf-1 expression
in both LGMD-1C cells could represent an additional mecha-
nism triggering myoﬁber degeneration, as normally the proper
increase of ubiquitin ligase expression and activity contributes
to myoblast diﬀerentiation, providing the required turn-over of
myoﬁbrillar proteins.
Indeed, since a clinical heterogeneity of symptoms is ob-
served in LGMD-1C patients, our data suggest that separated
mutations related to the same dystrophy associated-gene may
cause muscle degeneration through distinct mechanisms, trig-
gering diﬀerent phenotypic behaviors.Acknowledgements: We wish to thank Antonio Musaro` (University of
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